Cargando…
HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus
BACKGROUND: The interplay between HCV, DM, and DAA therapy is poorly understood. We compared HCV infection characteristics, treatment uptake, and treatment outcomes in patients with and without DM. METHODS: A retrospective cohort study was conducted using data from The Ottawa Hospital Viral Hepatit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652941/ https://www.ncbi.nlm.nih.gov/pubmed/36371200 http://dx.doi.org/10.1186/s12902-022-01198-x |
_version_ | 1784828584149385216 |
---|---|
author | Angel, Marina Petrosyan, Yelena Doyle, Mary-Anne Cooper, Curtis |
author_facet | Angel, Marina Petrosyan, Yelena Doyle, Mary-Anne Cooper, Curtis |
author_sort | Angel, Marina |
collection | PubMed |
description | BACKGROUND: The interplay between HCV, DM, and DAA therapy is poorly understood. We compared HCV infection characteristics, treatment uptake, and treatment outcomes in patients with and without DM. METHODS: A retrospective cohort study was conducted using data from The Ottawa Hospital Viral Hepatitis Program. Statistical comparisons between diabetes and non-diabetes were made using χ(2) and t-tests. Logistic regression analyses were performed to assess predictors of DM and SVR. RESULTS: One thousand five hundred eighty-eight HCV patients were included in this analysis; 9.6% had DM. Patients with DM were older and more likely to have cirrhosis. HCC and chronic renal disease were more prevalent in the DM group. Treatment uptake and SVR were comparable between groups. Regression analysis revealed that age and employment were associated with achieving SVR. Post-SVR HCC was higher in DM group. CONCLUSION: The high prevalence of DM in our HCV cohort supports screening. Further assessment is required to determine if targeted, early DAA treatment reduces DM onset, progression to cirrhosis and HCC risk. Further studies are needed to determine if optimization of glycemic control in this population can lead to improved liver outcomes. |
format | Online Article Text |
id | pubmed-9652941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96529412022-11-15 HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus Angel, Marina Petrosyan, Yelena Doyle, Mary-Anne Cooper, Curtis BMC Endocr Disord Research BACKGROUND: The interplay between HCV, DM, and DAA therapy is poorly understood. We compared HCV infection characteristics, treatment uptake, and treatment outcomes in patients with and without DM. METHODS: A retrospective cohort study was conducted using data from The Ottawa Hospital Viral Hepatitis Program. Statistical comparisons between diabetes and non-diabetes were made using χ(2) and t-tests. Logistic regression analyses were performed to assess predictors of DM and SVR. RESULTS: One thousand five hundred eighty-eight HCV patients were included in this analysis; 9.6% had DM. Patients with DM were older and more likely to have cirrhosis. HCC and chronic renal disease were more prevalent in the DM group. Treatment uptake and SVR were comparable between groups. Regression analysis revealed that age and employment were associated with achieving SVR. Post-SVR HCC was higher in DM group. CONCLUSION: The high prevalence of DM in our HCV cohort supports screening. Further assessment is required to determine if targeted, early DAA treatment reduces DM onset, progression to cirrhosis and HCC risk. Further studies are needed to determine if optimization of glycemic control in this population can lead to improved liver outcomes. BioMed Central 2022-11-12 /pmc/articles/PMC9652941/ /pubmed/36371200 http://dx.doi.org/10.1186/s12902-022-01198-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Angel, Marina Petrosyan, Yelena Doyle, Mary-Anne Cooper, Curtis HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus |
title | HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus |
title_full | HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus |
title_fullStr | HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus |
title_full_unstemmed | HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus |
title_short | HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus |
title_sort | hcv infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652941/ https://www.ncbi.nlm.nih.gov/pubmed/36371200 http://dx.doi.org/10.1186/s12902-022-01198-x |
work_keys_str_mv | AT angelmarina hcvinfectioncharacteristicstreatmentuptakeandoutcomesinpatientwithdiabetesmellitus AT petrosyanyelena hcvinfectioncharacteristicstreatmentuptakeandoutcomesinpatientwithdiabetesmellitus AT doylemaryanne hcvinfectioncharacteristicstreatmentuptakeandoutcomesinpatientwithdiabetesmellitus AT coopercurtis hcvinfectioncharacteristicstreatmentuptakeandoutcomesinpatientwithdiabetesmellitus |